Cystic Fibrosis
"Cystic Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Descriptor ID |
D003550
|
| MeSH Number(s) |
C06.689.202 C08.381.187 C16.320.190 C16.614.213
|
| Concept/Terms |
Pancreatic Cystic Fibrosis- Pancreatic Cystic Fibrosis
- Cystic Fibrosis, Pancreatic
- Fibrocystic Disease of Pancreas
- Pancreas Fibrocystic Disease
- Pancreas Fibrocystic Diseases
- Cystic Fibrosis of Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis".
This graph shows the total number of publications written about "Cystic Fibrosis" by people in this website by year, and whether "Cystic Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 1 | 5 | | 1997 | 3 | 1 | 4 | | 1998 | 4 | 1 | 5 | | 1999 | 2 | 1 | 3 | | 2000 | 4 | 0 | 4 | | 2001 | 5 | 2 | 7 | | 2002 | 12 | 0 | 12 | | 2003 | 8 | 1 | 9 | | 2004 | 13 | 0 | 13 | | 2005 | 15 | 4 | 19 | | 2006 | 13 | 3 | 16 | | 2007 | 22 | 3 | 25 | | 2008 | 13 | 3 | 16 | | 2009 | 18 | 1 | 19 | | 2010 | 21 | 3 | 24 | | 2011 | 15 | 1 | 16 | | 2012 | 19 | 1 | 20 | | 2013 | 3 | 2 | 5 | | 2014 | 21 | 3 | 24 | | 2015 | 25 | 0 | 25 | | 2016 | 29 | 1 | 30 | | 2017 | 24 | 1 | 25 | | 2018 | 30 | 4 | 34 | | 2019 | 35 | 1 | 36 | | 2020 | 44 | 0 | 44 | | 2021 | 53 | 2 | 55 | | 2022 | 55 | 0 | 55 | | 2023 | 61 | 0 | 61 | | 2024 | 35 | 4 | 39 | | 2025 | 44 | 1 | 45 | | 2026 | 29 | 3 | 32 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis" by people in Profiles.
-
Corley JM, Congel JH, Haist KC, Ochoa AE, Malcolm KC, Janssen WJ, Nick JA, Hisert KB. Tobramycin enhances Mycobacterium abscessus fitness through whiB7 induction. Proc Natl Acad Sci U S A. 2026 Sep 22; 123(38):e2626942123.
-
Fought MK, O'Connor JB, Wagner BD, Quinn AC, Kirk Harris J, Laguna TA. Cathepsin B, Airway Pathogens, and Inflammation in the Lower Airways of Children With Cystic Fibrosis. Pediatr Pulmonol. 2026 Aug; 61(8):e71793.
-
Duncan CL, von Isenburg M, Green A, Ford C, Pucci A, Muther EF, Riekert KA, Bord E, Hoppe JE, Bacon C, Goodman A, Lyons E, Prickett M, Gibson SL, Everhart RS. Caregiver Mental Health and Its Relation to Child and Adolescent Mental and Behavioral Health in the Era of Highly Effective Modulator Therapy for Cystic Fibrosis. Pediatr Pulmonol. 2026 Aug; 61(8):e71794.
-
Zemanick ET, Graeber SY, Castellani C, Cutting GR, Fajac I, Konstan MW, Linnemann RW, McKone EF, Metcalf A, Solomon GM, Taylor-Cousar JL, Mayer-Hamblett N, Mall MA. The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis. Lancet Respir Med. 2026 Aug; 14(8):704-716.
-
Calton MA, Croze RH, Sullivan TH, Collins SA, Tucker S, Whittlesey KJ, Kim DH, Nye JA, Beliakoff G, Quezada M, Burns C, Schmitt C, Klein A, Jia V, Kovacs L, Lauko D, Yoh K, Nguyen K, Barglow K, Gonzales J, Khoday D, Mason T, Delaria K, Bashour K, Kotterman M, Schaffer D, Song A, Francis P, Taylor-Cousar JL, Kirn D. Design and characterization of 4D-710, an aerosolized gene therapy for cystic fibrosis lung disease. Am J Respir Cell Mol Biol. 2026 Jul 01; 74(7):837-846.
-
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS. Impact of CFTR modulator concentrations on clinical response in cystic fibrosis. Eur Respir J. 2026 Jun; 67(6).
-
Leigh MW, Shapiro AJ, Chawla KK, Hazucha MJ, Brown DE, Lin FC, Jiang L, Carson JL, Davis SD, Dell SD, Sagel SD, Rosenfeld M, Milla C, Sullivan KM, Zariwala MA, Ferkol TW, Knowles MR. Tidal breathing nasal nitric oxide measurement as a test for primary ciliary dyskinesia in young children. Eur Respir J. 2026 Jun; 67(6).
-
Muther EF, Gibson SL, Ford C, Duncan C, Riekert KA, Lyons E, Hoppe JE, Prickett M, Isenburg MV, Everhart RS. People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor. Respir Med. 2026 Aug; 259:108908.
-
Matheson AM, Prather E, Willmering MM, Mata J, Santyr G, Ratjen FA, Kramer EL, Cleveland ZI, Woods JC. Lung mucus burden and treatment response assessed by MRI in the post-modulator era. J Cyst Fibros. 2026 Jul; 25(4):711-717.
-
Maher MD, Vigers T, Kohler C, Stecenko AA, Moran A, Chan CL, Phillips LS. Screening for Diabetes and Prediabetes in Cystic Fibrosis Using a Nonfasting 50-Gram 1-Hour Oral Glucose Challenge Test. Diabetes Care. 2026 May 01; 49(5):882-888.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|